![Alejandro Dorenbaum](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alejandro Dorenbaum
Corporate Officer/Principal bei
Stanford University School of Medicine
Profil
Dr. Alejandro Dorenbaum, MD, is a Chief Medical Officer at Reneo Pharmaceuticals, Inc. and a Clinical Professor-Pediatrics at Stanford University School of Medicine.
Dr. Dorenbaum was previously employed as a Chief Medical Officer by Allakos, Inc., a Chief Medical Officer by Lumena Pharmaceuticals, Inc., a Medical Director by Genentech, Inc., a Senior Director-Clinical Affairs by BioMarin Pharmaceutical, Inc., a Director-Clinical Development by Chiron Corp., and an Assistant Clinical Professor-Pediatrics by The University of California, San Francisco.
He received his doctorate degree from Universidad Nacional Autónoma de México.
Aktive Positionen von Alejandro Dorenbaum
| Unternehmen | Position | Beginn |
|---|---|---|
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Alejandro Dorenbaum
| Unternehmen | Position | Ende |
|---|---|---|
| ALLAKOS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2017 |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for rare liver diseases | Technik-/Wissenschafts-/F&E-Leiter | 30.06.2014 |
| BIOMARIN PHARMACEUTICAL INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2009 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Corporate Officer/Principal | 01.01.2003 |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.2000 |
Ausbildung von Alejandro Dorenbaum
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
69
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for rare liver diseases | Health Technology |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universidad Nacional Autónoma de México
 Universidad Nacional Autónoma de México Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allakos, Inc.
 Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
Stanford University School of Medicine
Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Reneo Pharmaceuticals, Inc.
 Reneo Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases | Health Technology |
